Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): A new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder

CNS Neuroscience and Therapeutics

Volumn 15, Issue 1, 2009, Pages 12-18

  Feltner, Douglas E ^a,c   Harness, Jane ^a   Brock, Jerri ^a   Sambunaris, Angelo ^b   Cappelleri, Joseph C ^a   Morlock, Robert ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Behavioral Medicine Institute of Atlanta   (United States)

^c PFIZER INC   (United States)

Author keywords

Anxiety; Benzodiazepine; Clinical trial; Generalized anxiety disorder; Measurement; Onset

Indexed keywords

LORAZEPAM; PAROXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DAILY ASSESSMENT OF SYMPTOMS ANXIETY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; TREATMENT OUTCOME;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PAROXETINE; SENSITIVITY AND SPECIFICITY;

EID: 60349085763     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00075.x     Document Type: Article

References (24)

1. ESEMeD/MHEDEA, 2000 Investigators ESotEoMD, (ESEMeD) Project Alonso JAM, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo GGR, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004 420 : 21 27.
2. Kessler RCDO, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KBZA. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005 352 : 2515 2523.
3. Kessler RCDR, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999 156 : 1915 1923.
4. Lieb RBE, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005 14 : 445 452.
5. Olfson MSS, Feder A, Fuentes M, Nomura Y, Gameroff M, Weissman MM. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 2000 9 : 876 883.
6. Maier WGM, Freyberger HJ, Linz M, Heun R, Lecrubier Y. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: A valid diagnostic entity? Acta Psychiatr Scand 2000 101 : 29 36.
7. Wittchen HUCR, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000 15 : 319 328.
8. Pande ACCJ, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJZD, Davidson JR, Liu-Dumaw M. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry 2003 160 : 533 540.
9. Graham SJ, Scaife JC, Langley RW, Bradshaw CM, Szabadi E, Xi L, Crumley T, Calder N, Gottesdiener K, Wagner JA. Effects of lorazepam on fear-potentiated startle responses in man. J Psychopharmacol 2005 19 : 249 258.
10. Wolf DL, Desjardins PJ, Black PM, Francom SR, Mohanlal RW, Fleishaker JC. Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: Evaluation of alprazolam. J Clin Psychopharmacol 2003 23 : 51 57.
11. Nardi AE, Valenca AM, Nascimento I, Mezzasalma MA, Zin WA. Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks. Psychiatry Res 2000 94 : 179 184.
12. Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004 161 : 1642 1649.
13. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001 62 : 350 357.
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959 32 : 50 55.
15. Morlock RFD, Fehnel S, Williams V, Cappelleri J, Harness J, Kavoussi R, Endicott J. Development and Evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J. Psychiatric Res 2008 42 : 1024 1036.
16. Devellis R. Scale development: Theory and applications. Thousand Oaks, CA : Sage Publications, Inc., 2003.
17. Guy W. ECDEU assessment manual for psychopharmacology (US Department of Health, Education, and Welfare Publication No. 76-338). Rockville, MD : National Institute of Mental Health, 1976 pp. 218 222.
18. Endicott JNJ, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993 29 : 321 326.
19. Ware JESC Jr. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 483.
20. Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL. Generalized anxiety disorder severity scale (GADSS): A preliminary validation study. Depress Anxiety 2006 23 : 77 82.
21. Stein DJ. Generalized anxiety disorder: Rethinking diagnosis and rating. CNS Spectr 2005 10 : 930 934.
22. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006 166 : 1092 1097.
23. Leon AC. Measuring onset of antidepressant action in clinical trials: An overview of definitions and methodology. J Clin Psychiatry 2001 62 (Suppl 4 12 16 discussion 37-40.
24. Montgomery SA, Bech P, Blier P, Moller HJ, Nierenberg AA, Pinder RM, Quitkin FM, Reimitz PE, Rosenbaum JF, Rush AJ, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002 63 : 694 699.